A New Class of Cell Therapies to Target Solid Tumors

Jason Bock, CEO of CMTC, the joint venture between Resilience and MD Anderson Cancer Center, discusses the emerging area of TIL therapies, the significance of the first approved therapy in the class, and how they may address existing limitations of CAR-T therapies.